NASDAQ:ITRM

Iterum Therapeutics Competitors

$1.32
-0.29 (-18.01 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.28
Now: $1.32
$1.42
50-Day Range
$1.36
MA: $1.60
$2.07
52-Week Range
$0.45
Now: $1.32
$6.02
Volume37.64 million shs
Average Volume25.53 million shs
Market Capitalization$232.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49

Competitors

Iterum Therapeutics (NASDAQ:ITRM) Vs. HGEN, RDUS, PRTA, VNDA, BTAI, and MRUS

Should you be buying ITRM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Iterum Therapeutics, including Humanigen (HGEN), Radius Health (RDUS), Prothena (PRTA), Vanda Pharmaceuticals (VNDA), BioXcel Therapeutics (BTAI), and Merus (MRUS).

Iterum Therapeutics (NASDAQ:ITRM) and Humanigen (NASDAQ:HGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Iterum Therapeutics and Humanigen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iterum Therapeutics$40,000.005,823.77$-103,130,000.00($7.10)-0.19
HumanigenN/AN/A$-10,290,000.00N/AN/A

Humanigen has lower revenue, but higher earnings than Iterum Therapeutics.

Profitability

This table compares Iterum Therapeutics and Humanigen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iterum TherapeuticsN/AN/A-179.51%
HumanigenN/A-302.90%-174.74%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Iterum Therapeutics and Humanigen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iterum Therapeutics02202.50
Humanigen01502.83

Iterum Therapeutics presently has a consensus target price of $3.25, indicating a potential upside of 146.21%. Humanigen has a consensus target price of $29.50, indicating a potential upside of 71.01%. Given Iterum Therapeutics' higher possible upside, equities research analysts plainly believe Iterum Therapeutics is more favorable than Humanigen.

Institutional and Insider Ownership

10.1% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Humanigen shares are owned by institutional investors. 22.1% of Iterum Therapeutics shares are owned by insiders. Comparatively, 37.5% of Humanigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Iterum Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Humanigen has a beta of -0.79, meaning that its share price is 179% less volatile than the S&P 500.

Summary

Humanigen beats Iterum Therapeutics on 6 of the 10 factors compared between the two stocks.

Radius Health (NASDAQ:RDUS) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.

Earnings & Valuation

This table compares Radius Health and Iterum Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Radius Health$173.32 million5.27$-132,990,000.00($2.89)-6.74
Iterum Therapeutics$40,000.005,823.77$-103,130,000.00($7.10)-0.19

Iterum Therapeutics has lower revenue, but higher earnings than Radius Health. Radius Health is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Radius Health and Iterum Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Radius Health-48.61%N/A-56.85%
Iterum TherapeuticsN/AN/A-179.51%

Analyst Recommendations

This is a summary of recent ratings and target prices for Radius Health and Iterum Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Radius Health06302.33
Iterum Therapeutics02202.50

Radius Health presently has a consensus price target of $24.60, indicating a potential upside of 26.22%. Iterum Therapeutics has a consensus price target of $3.25, indicating a potential upside of 146.21%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Iterum Therapeutics is more favorable than Radius Health.

Insider & Institutional Ownership

10.1% of Iterum Therapeutics shares are held by institutional investors. 2.9% of Radius Health shares are held by company insiders. Comparatively, 22.1% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Radius Health has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Summary

Iterum Therapeutics beats Radius Health on 9 of the 13 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

90.2% of Prothena shares are held by institutional investors. Comparatively, 10.1% of Iterum Therapeutics shares are held by institutional investors. 30.4% of Prothena shares are held by company insiders. Comparatively, 22.1% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Prothena and Iterum Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,125.11$-77,680,000.00($1.95)-11.68
Iterum Therapeutics$40,000.005,823.77$-103,130,000.00($7.10)-0.19

Prothena has higher revenue and earnings than Iterum Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prothena and Iterum Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Iterum TherapeuticsN/AN/A-179.51%

Risk and Volatility

Prothena has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Prothena and Iterum Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Iterum Therapeutics02202.50

Prothena currently has a consensus price target of $29.4286, indicating a potential upside of 29.19%. Iterum Therapeutics has a consensus price target of $3.25, indicating a potential upside of 146.21%. Given Iterum Therapeutics' higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Prothena.

Summary

Prothena beats Iterum Therapeutics on 9 of the 14 factors compared between the two stocks.

Iterum Therapeutics (NASDAQ:ITRM) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Iterum Therapeutics and Vanda Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iterum Therapeutics02202.50
Vanda Pharmaceuticals04102.20

Iterum Therapeutics currently has a consensus price target of $3.25, suggesting a potential upside of 146.21%. Vanda Pharmaceuticals has a consensus price target of $15.40, suggesting a potential downside of 5.23%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Iterum Therapeutics is more favorable than Vanda Pharmaceuticals.

Insider & Institutional Ownership

10.1% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 97.6% of Vanda Pharmaceuticals shares are held by institutional investors. 22.1% of Iterum Therapeutics shares are held by company insiders. Comparatively, 5.9% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Iterum Therapeutics and Vanda Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iterum Therapeutics$40,000.005,823.77$-103,130,000.00($7.10)-0.19
Vanda Pharmaceuticals$227.19 million3.93$115.55 million$2.117.70

Vanda Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Iterum Therapeutics and Vanda Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iterum TherapeuticsN/AN/A-179.51%
Vanda Pharmaceuticals8.02%4.56%3.88%

Summary

Vanda Pharmaceuticals beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks.

Iterum Therapeutics (NASDAQ:ITRM) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Iterum Therapeutics and BioXcel Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iterum Therapeutics02202.50
BioXcel Therapeutics001103.00

Iterum Therapeutics currently has a consensus price target of $3.25, suggesting a potential upside of 146.21%. BioXcel Therapeutics has a consensus price target of $101.8182, suggesting a potential upside of 183.85%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Iterum Therapeutics.

Insider & Institutional Ownership

10.1% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 22.1% of Iterum Therapeutics shares are held by company insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Iterum Therapeutics and BioXcel Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iterum Therapeutics$40,000.005,823.77$-103,130,000.00($7.10)-0.19
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.76

BioXcel Therapeutics has lower revenue, but higher earnings than Iterum Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares Iterum Therapeutics and BioXcel Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iterum TherapeuticsN/AN/A-179.51%
BioXcel TherapeuticsN/A-74.22%-64.31%

Summary

BioXcel Therapeutics beats Iterum Therapeutics on 7 of the 12 factors compared between the two stocks.

Merus (NASDAQ:MRUS) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Merus and Iterum Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merus01402.80
Iterum Therapeutics02202.50

Merus currently has a consensus target price of $27.80, suggesting a potential upside of 20.56%. Iterum Therapeutics has a consensus target price of $3.25, suggesting a potential upside of 146.21%. Given Iterum Therapeutics' higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Merus.

Earnings and Valuation

This table compares Merus and Iterum Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$31.13 million28.24$-55,150,000.00($2.33)-9.90
Iterum Therapeutics$40,000.005,823.77$-103,130,000.00($7.10)-0.19

Merus has higher revenue and earnings than Iterum Therapeutics. Merus is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merus and Iterum Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merus-295.98%-78.70%-36.12%
Iterum TherapeuticsN/AN/A-179.51%

Insider & Institutional Ownership

62.6% of Merus shares are owned by institutional investors. Comparatively, 10.1% of Iterum Therapeutics shares are owned by institutional investors. 7.4% of Merus shares are owned by insiders. Comparatively, 22.1% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Merus has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.


Iterum Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49-2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78-3.1%$911.34 million$810,000.00-8.90News Coverage
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87-0.4%$881.43 millionN/A-10.64Analyst Report
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.06-1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75-0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74-19.0%$860.30 million$23.96 million-16.51High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37-0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89-0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00News Coverage
Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88-2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82-3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32-9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58-2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23-2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87-6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52-3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07-4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44-2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20-5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56-0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10-0.6%$544.91 million$26.74 million17.75
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66-5.1%$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04-0.2%$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32-0.0%$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87-4.3%$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28-0.2%$524.18 millionN/A-5.20
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.